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A B S T R A C T
Purpose
Adjuvant chemotherapy for breast cancer can have adverse effects on cognition shortly after
administration. Whether chemotherapy has any long-term effects on cognition is largely unknown,
yet it becomes increasingly relevant because of the widespread use of chemotherapy for
early-stage breast cancer and the improved survival. We investigated whether cyclophosphamide,
methotrexate, and fluorouracil (CMF) chemotherapy for breast cancer is associated with worse
cognitive performance more than 20 years after treatment.
Patients and Methods
This case-cohort study compared the cognitive performance of patients with breast cancer who
had a history of adjuvant CMF chemotherapy treatment (six cycles; average time since treatment,
21 years; n  196) to that of a population-based sample of women never diagnosed with cancer
(n  1,509). Participants were between 50 and 80 years of age. Exclusion criteria were ever use
of adjuvant endocrine therapy, secondary malignancy, recurrence, and/or metastasis.
Results
The women exposed to chemotherapy performed significantly worse than the reference group on
cognitive tests of immediate (P  .015) and delayed verbal memory (P  .002), processing speed
(P .001), executive functioning (P .013), and psychomotor speed (P .001). They experienced
fewer symptoms of depression (P  .001), yet had significantly more memory complaints on two
of three measures that could not be explained by cognitive test performance.
Conclusion
Survivors of breast cancer treated with adjuvant CMF chemotherapy more than 20 years ago
perform worse, on average, than random population controls on neuropsychological tests. The
pattern of cognitive problems is largely similar to that observed in patients shortly after cessation
of chemotherapy. This study suggests that cognitive deficits following breast cancer diagnosis and
subsequent CMF chemotherapy can be long lasting.
J Clin Oncol 30:1080-1086. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Chemotherapy has well-recognized acute adverse
effects, including nausea and hair loss. Cognitive
impairment is a potential short-term adverse effect
that has gained more attention only in the last
decade.1-20 Several studies have shown that chemo-
therapy can induce cognitive changes up to 5 years
after treatment.2,5,14,20 Differences are primarily ob-
served in the domains of memory, processing speed,
andexecutive functionandaregenerallynot explained
by sociodemographic and clinical variables.21 Never-
theless, cognitive dysfunction has also been ob-
served in the domains of visuospatial functioning22
and psychomotor speed.15 Potential predictors for
cognitive problems, such as cognitive reserve and
genetic susceptibility, in patients with breast can-
cer who have been exposed to chemotherapy are
topics of ongoing research.23 Besides differences in
cognitive performance, structural brain differences
have been observed in patients who underwent
chemotherapy compared with controls, including
more white-matter hyperintensities, microstruc-
tural damage towhite-matter tracts, andgraymatter
alterations,1,7,24-30 whereas functional magnetic res-
onance imaging (fMRI) studies revealedmeasurable
differences in task-specific responsiveness between
patients exposed to chemotherapy and con-
trols.5,26,31 The observational studies in humans are
strongly supported by animal studies.32
Whether chemotherapy has long-term effects
onbrain function is still largely unknown.However,
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this question is becoming increasingly relevant because the number of
long-term survivors is rapidly increasing.
We investigated the late effects of chemotherapy on cognitive
functioningbycomparing theneuropsychological testperformanceof
womenwith breast cancerwho received adjuvant cyclophosphamide,
methotrexate, and fluorouracil (CMF) chemotherapy on average
more than 20 years before that of a population sample of womenwho
had never been diagnosed with cancer.
PATIENTS AND METHODS
Participants
Our case group consisted of survivors of breast cancer who had under-
gone adjuvant chemotherapy in either of two specialized cancer clinics in the
Netherlands. The reference group of controls was selected from an ongoing
population study in the Netherlands. The review boards of the participating
institutes (theNetherlandsCancer Institute/Antoni van LeeuwenhoekHospi-
tal and the Erasmus UniversityMedical Center) approved this study.
Patients Exposed to Chemotherapy
Fromtheregistriesof theNetherlandsCancer Institute/AntonivanLeeu-
wenhoek Hospital and the Erasmus University Medical Center-Daniel den
Hoed Cancer Center, we identified consecutive female patients with breast
cancer who, as part of their primary treatment had received six cycles of
adjuvantCMFchemotherapy (cyclophosphamide 100mg/m2orally ondays 1
through 14, methotrexate 40 mg/m2 intravenously on days 1 and 8, and
fluorouracil 600 mg/m2 intravenously on days 1 and 8) between 1976 and
1995.Eligibility criteria includedagebetween50and80years at recruitment in
2008 and sufficient command of theDutch language.Only thosewomenwho
never had a relapse, secondary primary tumor, or distant metastasis were
selected. Exclusion criteria were ever use of adjuvant endocrine therapy and
contraindications forMRI.
Potential participants (n 359) were sent an invitation letter and infor-
mation on the study. Twenty patients (5.6%) could not be reached either
because their current address was unavailable, or they did not respond to the
invitation or subsequent reminders. Fifteen patients (4.2%) had a health-
related contraindication for MRI, 30 (8.4%) were ineligible for MRI assess-
ment because of claustrophobia, and two patients (0.6%) had insufficient
commandof theDutch language.Thefinalnumberof eligiblepatientswas292
of whom 196 (67.1%) eventually agreed to participate and provided written
informed consent. Examinations were performed between October 2008 and
October 2009.
Main reasons for decline were not wanting to be reminded of the cancer
episode (21.9%) and unwillingness to undergo MRI assessment (26.0%).
Decliners were older than participants (F1,290 12.24; P .001).
To assess possible selection bias, eligible womenwho declined participa-
tion andwomen forwhomclaustrophobiawas theonly contraindicationwere
invited to complete the interview and the neuropsychological assessments at
home. Test results of these initial decliners were compared with the results of
those who participated in this study. Of the 126 invited initial decliners (96
decliners30claustrophobicwomen), 48 (38.1%)agreed toparticipate.They
were assessed between November 2009 and June 2010.
Reference Group
A reference group was selected from the Rotterdam Study,33 a
population-based prospective cohort study ongoing since 1990 in Rotterdam,
theNetherlands. By the end of 2008, 14,926 participants had been included in
three separate subcohorts. Rotterdam Study III is the most recent subcohort,
comprising3,932personswhohavebeenassessedonlyoncebetweenFebruary
2006 andDecember 2008. To date, it is the only cohort that has been assessed
with an extensive set of neuropsychological tests and is therefore the most
appropriate reference subcohort.
From Rotterdam Study III, we selected all women without a history of
cancer on the basis of self-reports and linkage with data from their general
physician, who were between 50 and 80 years of age at the time of neuropsy-
chological assessment. In total, 1,509 participants met these criteria.
Methods
Examination of the participants took place at the Rotterdam Study
research center.34 Participants underwent neuropsychological examinations
and an interview identical with those used in the Rotterdam Study. Subse-
quently, bloodwas drawn, height andweightweremeasured, andparticipants
underwent MRI of the brain, carotid ultrasound imaging, and an electrocar-
diogram. Results from the latter measures will be described separately.
Neuropsychological Examination
Seven neuropsychological tests were administrated and scored by expe-
rienced test assistants from the Rotterdam Study. These tests yielded 17 out-
comes in the following cognitive domains: processing speed, verbal learning,
memory, inhibition and word fluency as elements of executive functioning,
visuospatial ability, and psychomotor speed. In addition, the Mini-Mental
State Examination (MMSE) was included as a dementia screener. For an
overview of the tests and domains,35-42 see Table 1.
Interview
Participants completed an interview on clinical and sociodemographic
factors, which included questions regarding medical history of neurologic,
psychiatric, and cardiovascular diseases. Depressive symptoms were assessed
with theCenter for Epidemiologic StudiesDepression scale (CES-D),43 which
was converted to a sum-score according to the standard scoring rules.44 Sub-
jectivememorycomplaintsweremeasuredwith threeyes/noquestions: (1)Do
youhavemore problems remembering things than before? (2)Has there been
an increase in the times that you forgot what you were up to? and (3) Do you
have more word-finding problems than before? Subsequently, participants
were asked whether these problems had an acute onset (yes/no) and if the
severity of the problems had changed over time (no change/problems in-
creased/problems decreased).
Statistical Analysis
We compared differences in sociodemographic variables between
groups bymeans of binary, ordinal, andmultinomial logistic regression anal-
ysis. Group differences in neuropsychological performance and depressive
symptoms were investigated with analysis of covariance, adjusted for age and
education. Although studies on the cognitive effects of chemotherapy shortly
after treatment do not show a strong relationship between depressive symp-
toms and neuropsychological performance,45 no information is available on
thispotential association longafter chemotherapy.Therefore,wesubsequently
adjustedour analyses forCES-Dsum-score.WeusedBonferroni correction to
account for multiple testing.
The age distribution of the reference group was more skewed toward
younger ages than thatof the survivorsof cancer exposed to chemotherapy.To
check whether any residual confounding by age remained after standard ad-
justment for age, we executed all analyses with propensity scores for age and
used an age-matched reference group randomly drawn from the total refer-
ence group. Since these additional analyses yielded results similar to those of
the primary analyses, their results are not separately reported.
Although the different cognitive tests in our battery were intended to
measuredifferent domains, an individual’s scores on cognitive testswereoften
related.Toaccount for this interdependencybetween test scores,we calculated
for each individual theMahalanobis Distance (MD)46 as a summarymeasure
of overall performance.47 TheMDtakes into account the correlations between
test scores and the different variances of the test scores and can be interpreted
as the distance to themean of themultidimensional distribution of the neuro-
psychological test scores of the reference group.
MD was based on all tests, except for the Design Organization test
because few women from the reference group completed this test and the
MMSE because it screens for dementia. We calculated age, education, and
CES-D score-adjusted residuals of the neuropsychological tests, although the
computation of the relevant means and (co)variances was based on the resid-
uals of the reference group.47,48 We assigned a value of zero to all residual
scores that were greater than their respective mean score from the reference
group, such that positive test scores could not compensate for negative
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scores.49 We transformed the MD with log base 2 because of skewness of its
distribution and subsequently used one-way analysis of variance to compare
MD between the patients exposed to chemotherapy and the reference group.
Spearman rank correlation coefficients with two-sided P values were
calculated to obtain the associations between memory complaints, neuro-
psychological test outcomes, andmood. For all analyses, levels were set at
P .05.
RESULTS
Table 2 presents the baseline characteristics of the patients with breast
cancer who were exposed to chemotherapy and the reference group.
Onaverage, survivorsof breast cancerwereolder andhadcompleteda
higher level of education. They had been diagnosed, on average, at age
42.9 and received chemotherapy, on average, 21.2 years before enroll-
ment onto this study. No differences were observed in the prevalence
of neurologic, psychiatric, or cardiovascular diseases.
Neuropsychological Outcomes
On all neuropsychological tests, survivors of breast cancer who
had been exposed to chemotherapy performed similar to or worse
than those in the reference group. These differences were significant
for nearly all trials of immediate and delayed recall of the 15-Word
LearningTest (15-WLT), for thecolor cardand thecolor-wordcardof
the Stroop test, and for nondominant-hand performance on the Pur-
due pegboard test (Table 3; Fig 1). After Bonferroni corrections, dif-
ferences on the 15-WLT delayed recall, the Stroop color card, and the
Purduepegboard test for thenondominant-handcondition remained
significant. MMSE scores did not differ between groups. Excluding
participantswithneurologic or psychiatric diseases didnot change the
outcome of the analyses.
The log base 2 of the MD was significantly larger for survivors
exposed to chemotherapy (mean, 2.8; standard deviation [SD], 2.6)
than for the reference group (mean, 2.2; SD, 2.8;F1,1648, 7.3;P .007),
indicating that the former had worse overall cognitive performance.
Time since diagnosis was not associatedwith neuropsychological per-
formance in survivors exposed to chemotherapy.
Depressive Symptoms and Memory Complaints
The reference group reported significantly more depressive
symptoms than the survivors of breast cancer exposed to chemo-
therapy (age-adjusted mean sum-score of the reference group on
the CES-D, 6.7; SD, 8.4; age-adjusted mean sum-score of the
chemotherapy-exposed survivors on the CES-D, 4.7; SD, 8.0;
F1,1696, 9.54; P  .002). There was a low correlation between
memory complaints and total score on the CES-D (  .275;
P .001) in survivors exposed to chemotherapy.
Table 1. Outcome Measures
Neuropsychological
Test Functional Area Assessed Reference Test Element Outcome Measure Range
MMSE Dementia screener Folstein et al36;
Tombaugh at al38
— Total correct answers 0-30
15-WLT Learning and memory Kalveboer et al37 Immediate recall
(3 trials)
No. of words remembered immediately after
each trial
(3) 0-15
Delayed recall No. of words remembered after 20 minutes 0-15
Recognition No. of words recognized 0-30
LDST Processing speed van der Elst42 — No. of correctly substituted letters 0-125
Stroop Color-Word
Test
Processing speed and inhibition as an
element of executive function
(abbreviated version)
Houx et al39 Word card Seconds needed to complete the first 4 lines†  0
Color card Seconds needed to complete the first 4 lines†  0
Color-word card Seconds needed to complete the first 4 lines†  0
WFT Verbal fluency (executive function) van der Elst et al41 — No. of animals mentioned within 1 minute  0
DOT Visuospatial ability Killgore et al40 — No. of correctly coded blocks 0-56
PPB Motor speed and dexterity Tiffin et al35 Left hand No. of pins inserted in the board within 1 minute 0-25
Right hand No. of pins inserted in the board within 1 minute 0-25
Both hands No. of pins inserted in the board within 1 minute 0-25
Abbreviations: 15-WLT, 15-Word Learning Test; DOT, Design Organization Test; LDST, Letter Digit Substitution Test; MMSE, Mini-Mental State Examination; PPB,
Purdue Pegboard test; SD, standard deviation; WFT, Word Fluency Test.
Higher score indicates better performance.
†Lower score indicates better performance.
Table 2. Sociodemographic and Clinical Characteristics of Former Patients
With Breast Cancer Exposed to Chemotherapy and the Reference Group
From the General Population
Characteristic
Patients Exposed
to Chemotherapy
(n  196)
Reference Group
(n  1,509)
P% Mean SD % Mean SD
Age, years 64.1 6.4 57.9 5.4  .001
Education level  .001
Primary 8.7 12.5
Lower vocational 16.3 21.5
Intermediate general 20.4 24.2
Intermediate vocational 16.8 16.3
Higher general 5.6 5.2
College 23.5 16.1
University 8.7 4.2
Age at breast cancer
diagnosis, years 42.9 5.3
Time since breast cancer
diagnosis, years 21.2 4.4
Abbreviation: SD, standard deviation.
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Theproportionof patientswho reported problemswith remem-
bering did not differ between groups, yet survivors of breast cancer
who were exposed to chemotherapy were more likely to report an
increase in word-finding problems and in the frequency of forgetting
pursuits (Table 4). These subjective memory complaints were not
related to neuropsychological performance.
Survivors of breast cancer exposed to chemotherapywho partic-
ipated at the Rotterdam Study research center did not differ from
participants who declined participation at the research center but
agreed tocognitive testing in theirownhomeregardingage, education
level, Bonferroni-corrected cognitive scores, ormood status.Without
correction for multiple testing, home participants performed worse
than center participants ononeof the 17 cognitivemeasures: theword
card of the Stroop test (P .011).
DISCUSSION
To the best of our knowledge, this is the first report on the cognitive
effects of adjuvant CMF chemotherapy in survivors of breast can-
cer who completed their treatment, on average, more than 21 years
before. Compared with women from the general population with-
out cancer, survivors of breast cancer who were exposed to chem-
otherapy performedworse on cognitive tests covering the domains
of learning, immediate and delayed verbal memory, information
processing speed, inhibition, and psychomotor speed. No differ-
ences were observed in scores on a dementia screener. The results
persisted after controlling for several confounders including age,
education level, and depression score. After subsequent correction
for multiple comparisons, survivors exposed to chemotherapy still
performed worse on tests measuring delayed verbal memory, pro-
cessing speed, and psychomotor speed. In addition, on a summary
measure of the neuropsychological tests that takes correlations
between multiple measures into account, survivors exposed to
chemotherapy performed significantly worse than women from
the general population.
Further, survivors of breast cancer exposed to chemotherapy
more often reported memory complaints, which were not associated
with test performance but were weakly correlated with mood. Survi-
vors exposed to chemotherapy had fewer depressive symptoms than
the reference group, although both groups scored below the cutoff
score of 16, which is indicative for clinical depression.43
Strengths of our study are the large sample size, the long
interval since chemotherapy, the homogeneous study population
regarding cytotoxic agents (regimen, cycles), and the large
population-based reference group without cancer. Possible selec-
tion bias within the chemotherapy-exposed group has been inves-
tigated and was found to be unlikely.
We compared chemotherapy-exposed survivors of breast
cancer to a population-based sample of healthy controls without a
history of cancer because we wanted to investigate to what extent
chemotherapy-exposed survivors of breast cancer deviate from the
norm regarding cognitive functioning. Subsequently, because ta-
moxifen was not part of standard treatment in the Netherlands
until the mid 1990s, it was not possible to include a comparison
group of long-term tamoxifen-exposed survivors. Because of our
design, we were unable to distinguish the effect of chemotherapy
on cognition from the possible effect of breast cancer itself.
It has been suggested that patientswithbreast cancermayalready
perform worse on tests of cognitive function compared with healthy
controls before the start of chemotherapy.8-10,15,18,50,51 Since we do
nothavepretreatment assessments touse for adjustingour results, our
findings might partially reflect group differences already present be-
fore chemotherapy. Themechanisms for pretreatment differences are
Table 3. Neuropsychological Test Outcomes
Test Outcome
Patients With Breast
Cancer Exposed to
Chemotherapy
(n 196)
Reference Group
(n  1,518)
PNo. Mean SD No. Mean SD
MMSE 196 28.4 2.0 1,507 28.2 2.2 .09
15-WLT: trial 1 194 5.5 2.2 1,397 5.9 2.4 .008
15-WLT: trial 2 194 8.6 2.4 1,397 9.0 2.7 .02
15-WLT: trial 3 194 10.3 2.6 1,397 10.6 2.9 .17
15-WLT: total of 3 trials 194 24.3 6.2 1,397 25.5 6.9 .02
15-WLT: delayed recall 194 8.0 2.9 1,397 8.7 3.2 .002
15-WLT: recognition 194 13.8 1.8 1,397 13.8 2.0 .76
LDST: total correct 195 31.8 6.7 1,497 32.5 7.5 .14
Stroop: word card 195 16.8 3.3 1,404 16.5 3.7 .14
Stroop: color card 195 23.3 4.4 1,404 22.2 4.9 .001
Stroop: color-word card 195 45.8 12.6 1,404 43.5 14.0 .02
Word fluency: total 194 24.1 6.1 1,490 24.2 6.8 .89
Word fluency: after 15
seconds 194 13.8 4.8 1,490 13.8 5.4 .95
DOT: total correct 195 28.9 9.2 511 28.9 9.7 .99
PPB: both hands 195 11.1 1.6 1,494 11.2 1.8 .56
PPB: dominant hand 195 13.8 1.9 1,490 13.8 2.1 .81
PPB: nondominant hand 195 12.9 1.8 1,490 13.4 2.0 .001
Abbreviations: 15-WLT, 15-Word Learning Test; DOT, Design Organization
Test; LDST, Letter Digit Substitution Test; MMSE, Mini-Mental State Exami-
nation; PPB, Purdue Pegboard test; SD, standard deviation.
Difference of the Z scores (95% CI)
Chemotherapy worse | Chemotherapy better 
-0.5 -0.3 -0.1 0.1
MMSE
15-WLT: trial 1
15-WLT: trial 2
15-WLT: trial 3
15-WLT: total of 3 trials
15-WLT: delayed recall
15-WLT: recognition
LDST: total correct
Stroop: word card
Stroop: color card
Stroop: color-word card
Word fluency: total
Word fluency: after 15 seconds
DOT: total correct
PPB: both hands
PPB: dominant hand
PPB: nondominant hand
0.3 0.5
Fig 1. Difference between standardized (Z) scores of the chemotherapy-
exposed survivors of breast cancer and reference subjects. 15-WLT, 15-Word
Learning Test; DOT, Design Organization Test; LDST, Letter Digit Substitution
Test; MMSE, Mini-Mental State Examination; PPB, Purdue Pegboard test.
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largely unknown, although the prevalence of cognitive problems at
baseline has been associated with the stage of breast cancer.51 Sug-
gested explanations for pretreatment problems include diminished
cognitive reserve, stimulation of proinflammatory cytokines,18 and
the effect of anesthetic drugs received for breast surgery.52 Because the
effect of anesthesia is transient,52 we consider its influence on cogni-
tionmore than 20 years post treatment unlikely.Moreover, follow-up
studies demonstrated a larger prevalence of cognitive decline from
baseline in chemotherapy-exposed patients than in patients who un-
derwent only locoregional therapy, indicating that at least part of the
deficits are indeed associated with cytotoxic treatment.3,15,53-56
Although information on hormone replacement therapy was
not available, we do not think this confounded our findings in any
significant way because the use of hormone replacement therapy in
the Netherlands tended to be low in the years under study ( 2.5%
of women age 40 to 74 years).57
An important question is to what extent our observations
extend to other chemotherapy regimens. The CMF regimen is no
longer the most optimal adjuvant chemotherapy for early-stage
breast cancer. However, it was the standard regimen up to the
1990s, and it is the only regimen that enables the investigation of
the late effects of chemotherapy in sufficiently large numbers of
patients. In addition, there is still an extensive groupofwomenwhohave
been treatedwithCMF in the late 1990s, some ofwhommay experience
itscognitiveadverseeffectsinthefuture.Furthermore,cyclophosphamide
and fluorouracil continue to be incorporated into currently used regi-
mens for early-stage breast cancer. Even if the findings of our studywere
specific toCMF, theywould remain relevant.
Several studies have found impairments in cognitive domains in
patientswith cancer shortly after treatmentwith chemotherapy.4, 58-65
Impairments frequently observed in chemotherapy-exposed patients
with breast cancer are learning problems and deficits in memory
retrieval with more preserved retention, as well as problems with
information processing speed andmore complex aspects of attention.
Imaging studies showed that some chemotherapy regimens may in-
duce structural brain alterations.1,7,24,25,27,28
This study resembles this pattern: chemotherapy-exposed
survivors of breast cancer from our study also had more problems
with learning and memory retrieval although retention was intact.
The combination of worse processing speed, inhibition problems,
and problems with fine motor functioning that we observed in
chemotherapy-exposed survivors adds to this profile. This profile
is suggestive for disruption of the frontal-subcortical network and
matches the profile observed in other studies.65
The fact that chemotherapy-exposed survivors of breast cancer
performed worse on the nondominant condition of the Purdue peg-
board test, but not on the dominant condition, has been observed
before in patients treated with chemotherapy7 and other patient pop-
ulations. It has been related to neurologic damage66 andmay possibly
be related to interhemispheric transfer deficits.67
Ourneuropsychological test batterywas identicalwith the oneused
in the Rotterdam Study but less extensive than some used in previous
studies.15,22,54,68,69 Somedomains (eg, visualmemory),whichareknown
tobeaffectedby cytotoxic treatment,werenot explicitly examined.15,22,70
Althoughwefoundseveralsignificantdifferencesincognitivefunctioning
between chemotherapy-exposed survivors and the reference group, we
mayhaveunderestimated the effects ofCMFchemotherapyoncognitive
functioning.Theeffectsofchemotherapymightextendtomorecognitive
domains thanwe showed in this study.
When we compare our study outcomes with those of other
studies investigating the cognitive effects of CMF chemotherapy,
there are several similarities. One study20 showed that patients who
underwentCMFat least 10 years ago performedworse thanhealthy
controls on tests measuring executive functioning, psychomotor
speed, and attention. Another study71 found that a subgroup of
patients treated with CMF showed impaired information process-
ing speed 5 years after completion of treatment. Animal studies
support our findings and have pointed out that methotrexate,
cyclophosphamide, and the combination of fluorouracil and
methotrexate are associated with impaired learning and memory
and structural brain changes.32,72-76
In conclusion, the cognitive functioning of survivors of breast
cancer on average 21 years after adjuvant CMF chemotherapy is
worse than that of women from the general population who have
never been diagnosed with cancer. These data suggest that cogni-
tive deficits following breast cancer diagnosis and subsequent CMF
chemotherapy are at least partially long lasting. Our results are
highly relevant in the field of survivorship because, with the current
treatment strategies, the number of long-term survivors of breast
cancer is increasing because of improved recognition of early-stage
Table 4. Subjective Cognitive Complaints in Patients With Breast Cancer Exposed to Chemotherapy and in a Reference Group From the General Population
Memory Complaints Exact Question
Patients Exposed to
Chemotherapy (%)
Reference
Group (%) OR 95% CI P
More problems remembering Do you have more problems remembering things
than before?
52.8 46.1 1.32 0.96 to 1.82 .09
Forgetting (daily) pursuits Has there been an increase in the times that you
forgot what you were up to?
42.9 35.2 1.41 1.01 to 1.96 .042
Word-finding problems Do you have more word-finding problems than
before?
38.2 30.2 1.46 1.04 to 2.05 .030
Rapid onset of problems Did the problems occur suddenly? 10.7 13.4 0.76 0.36 to 1.62 .48
Change in problems Have the problems changed over time?
Worsened over time Reference† 30.5 19.6 1.68 0.99 to 2.82 .05
Improved over time Reference† 5.8 6.5 0.98 0.36 to 2.65 .97
Abbreviations: CES-D, Center for Epidemiologic Studies Depression scale; OR, odds ratio.
Depression score (CES-D) and age adjusted.
†No change over time.
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breast cancer, aging of the population, and improved survival after
breast cancer diagnosis.77,78 Further studies into the late effects of
adjuvant chemotherapy for cancer are needed to corroborate these
results and to gain further insight into the mechanisms underlying
these observations.
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